(in millions, except per share data) | Quarter Ended March 31, 2024 | Full-Year Ended December 31, 2024 | |||||||||||||||||||||||||||||||||
Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
Low | High | Low | High | ||||||||||||||||||||||||||||||||
Previously announced guidance excluding Q1 2024 acquired IPR&D and milestones expense | $ | — | $ | 2.26 | $ | 2.30 | $ | — | $ | 11.05 | $ | 11.25 | |||||||||||||||||||||||
Q1 2024 acquired IPR&D and milestones expense | 164 | (0.08) | (0.08) | 164 | (0.08) | (0.08) | |||||||||||||||||||||||||||||
Guidance including Q1 2024 acquired IPR&D and milestones expensea | $ | 164 | $ | 2.18 | $ | 2.22 | $ | 164 | $ | 10.97 | $ | 11.17 |